News Quantified

RNAC – cartesian therapeutics, inc. (US:NASDAQ)

Cartesian Therapeutics (NASDAQ:RNAC) had its price target raised by analysts at Needham & Company LLC from $40.00 to $42.00. They now have a "buy" rating on the stock.

1/9

08:13 am

rnac

Medium

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook [Yahoo! Finance]

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors [Yahoo! Finance]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}